WuXi AppTec launches closed process CAR-T platform

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Mouu007)
(Image: Getty/Mouu007)

Related tags: Wuxi apptec, WuXi Advanced Therapies, CAR-T

The cell therapy platform will provide development, manufacturing and release services to companies working on CAR-T therapies.

The platform will be released through WuXi AppTec’s subsidiary, WuXi Advanced Therapies, which is a contract development and manufacturing organization (CDMO) for cell and gene therapies. While the platform itself aims to accelerate the timelines for the development of chimeric antigen receptor (CAR)-T therapies.

The ‘closed process’ system will contain everything necessary to take a clinical candidate through development with the CDMO having integrated capabilities for CAR-T production.

WuXi stated that this includes in-stock raw materials; full in-process and release testing; regulatory and technical expertise; process and analytical development; quality control and quality assurance oversight; as well as access to the CDMO’s facilities.

The organization suggested that the platform will ‘increase the speed’ to bring new cell and gene therapies to market.

As part of the platform, there are two modalities that depend on dose requirement, with each using a list of pre-evaluated equipment, technologies and materials for the closed processes.

Last month, WuXi Advanced Therapies launched a fully integrated adeno-associated virus (AAV) vector suspension platform, which aims to provide the same specialized service as the CAR-T platform.

Both AAV-reliant cell and gene therapies and CAR-T therapies form an integral part of the growing pipeline​ of such therapies.

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Related suppliers

Follow us


View more